GlassScriptPhysician profile
Monika Korff
NPI 1457385601
$4,655.79
in general payments reported to CMS, 2019-2025
27 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $258 · 2021: $358 · 2022: $599 · 2023: $1,024 · 2024: $878 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128 · Education: $72.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.96 |
| Education | $72.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,397.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $963.54 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $344.34 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $323.87 | 2019-2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $309.81 | 2023-2025 | Dupixent |
| Optinose US, INC. | $187.34 | 2020-2025 | |
| Blueprint Medicines Corporation | $160.00 | 2022-2024 | Ayvakit |
| Abbvie INC. | $149.06 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $139.31 | 2019-2025 | |
| Lilly USA, LLC | $100.42 | 2024-2025 | Ebglyss, Taltz |
| Pfizer INC. | $82.05 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Organon LLC | $55.24 | 2025 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $54.39 | 2022-2024 | |
| Ars Pharmaceuticals Operations, INC. | $49.50 | 2025 | Neffy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $39.72 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.78 | 2022 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Hikma Pharmaceuticals USA | $27.20 | 2024 | Ryaltris |
| Leo Pharma INC. | $24.06 | 2025 | Anzupgo |
| Arcutis Biotherapeutics, INC. | $22.14 | 2025 | Zoryve |
| Incyte Corporation | $21.54 | 2025 | Opzelura |
| Amgen INC. | $21.41 | 2025 | Tezspire |
| Pharming Healthcare, INC. | $18.29 | 2023 | Ruconest |
| Csl Behring | $16.91 | 2025 | Haegarda, Andembry |
| Ionis Pharmaceuticals, INC. | $16.42 | 2025 | Dawnzera |
| Phadia US INC. | $13.42 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monika Korff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.